Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [23]. Core Insights - The pharmaceutical sector experienced a decline of 4.4% this week, underperforming the Shanghai Composite Index, which fell by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 28.7 times PE (2025E), ranking it 5th among 31 sub-industries [5][10]. - Recent policies from the National Medical Products Administration (NMPA) aim to support the development of high-end medical devices and accelerate the clinical review process for innovative drugs [12]. - Shengnuo Biopharma forecasts a significant profit increase for H1 2025, with expected net profit ranging from 77.03 million to 94.14 million yuan, marking a year-on-year growth of 253.54% to 332.10% [13]. Market Performance - The pharmaceutical and biotechnology index ranked 29th out of 31 sub-industries this week, with various segments showing declines, including chemical preparations (-5.7%) and medical devices (-3.7%) [2][5]. - The report highlights the strong growth in product revenue and licensing deals in the innovative drug sector over the past three years, with a focus on companies expected to release major products and those involved in the CXO industry [12]. Key Events - The NMPA has approved measures to encourage the innovation of high-end medical devices, including optimizing special approval processes and enhancing regulatory frameworks [12]. - The NMPA has also proposed a 30-day review process for clinical trial applications of innovative drugs, aimed at improving the efficiency of drug development [12].

一、股东大会审议通过权益分派方案情况 度权益分派方案。具体方案为：以分配方案未来实施时股权登记日享有利润分配 权的股本总额为基数，拟向全体股东每 10 股派发现金股利人民币 11 元（含税）， 不送红股，不以资本公积金转增股本。公司剩余未分配利润留待以后年度分配。 本次利润分配方案实施时，如因新增股份上市、股份回购、库存股完成股权激励 过户、回购注销等原因使得享有利润分配权的股份总额发生变动，公司将按照分 配比例固定的原则对分配总金额进行相应调整。 股变更为 333,040,460 股，系公司回购注销 2020 年限制性股票激励计划预留授 予离职激励对象 1,680 股股份所致，具体内容详见公司 2025 年 5 月 27 日刊登于 《中国证券报》、 证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 关于 2024 年年度权益分派实施的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 特别提示 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"）2024年度 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以公司目前A股总股本333,040,460为基数，扣除公司 回购专用账户中的回购股份总数1,442,700股）,公司本次A股现金分红共计 364,757,536.00元（含税）。 2、因公司回购账户股份不参与分红，本次权益分派实施后，根据股票市值 不变原则，实施权益分派前后公司A股总股本保持不变，现金分红总额分摊到每 一股的比例将减小。本次权益分派按公司总股本折算的每股现金红利为 1.0952349元/股（计算结果直接截取小数点后七位，不四舍五入）。本次权益分 派实施后的除权除息参考价=除权除息日前一交易日收盘价-按公司总股本折算 每股现金分红金额=股权登记日收盘价-1.0952349元/股。 一、股东大会审议通过权益分派方案情况 1、2025 年 6 月 11 日公司召开 2024 年度股东大会，审议通过了 202 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

证券代码：002821 证券简称：凯莱英 公告编号：2025-036 凯莱英医药集团（天津）股份有限公司 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开与出席情况 （一）会议召开情况 网络投票时间：2025年6月11日（周三），其中，通过深圳证券交易所交易 系统进行网络投票的时间为2025年6月11日上午9：15-9：25，9：30-11：30，下 午13:00-15:00；通过深圳证券交易所互联网投票系统投票的时间为2025年6月11 日上午9:15至2025年6月11日下午15:00期间的任意时间。 及《公司章程》的有关规定。 （二）会议出席情况 （1）2024年度股东大会出席情况 其中：A股股东人数 518 境外上市外资股股东人数（H股） 2 其中：A股股东持有股份总数（股） 184,262,000 境外上市外资股股东持有股份总数（H股） 7,706,059 份总数的比例 其中：A股股东持股占有表决权股份总数的比例 52.4016% 境外上市外资股股东持股占有表决权股份总数的比例 2.1915% 注1：通过现场投票的A股股东7人，代 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-036 凯莱英医药集团（天津）股份有限公司 2024 年度股东大会、2025 年第二次 A 股类别股东大会及 特别提示： 1、本次股东大会没有出现议案被否决的情形； 2、本次股东大会没有涉及变更前次股东大会决议的情形； 3、本次股东大会以现场投票与网络投票相结合的方式召开。 一、会议召开与出席情况 （一）会议召开情况 1、 现场会议召开时间：2025年6月11日（周三）下午14:00 网络投票时间：2025年6月11日（周三），其中，通过深圳证券交易所交易 系统进行网络投票的时间为2025年6月11日上午9：15-9：25，9：30-11：30，下 午13:00-15:00；通过深圳证券交易所互联网投票系统投票的时间为2025年6月11 日上午9:15至2025年6月11日下午15:00期间的任意时间。 2、会议召开地点：天津经济技术开发区第七大街71号公司会议室 2025 年第二次 H 股类别股东大会决议公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 3、会议召开方式：现场投票和网络投票相结合方 ...

北京德恒律师事务所 关于 凯莱英医药集团（天津）股份有限公司 2024 年度股东大会、2025 年第二次 A 股类别股东大会 及 2025 年第二次 H 股类别股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于凯莱英医药集团（天津）股份有限公 司 2024 年度股东大会、2025 年第二次 A 股类别股东大会 及 2025 年第二次 H 股类别股东大会的法律意见 北京德恒律师事务所 关于 凯莱英医药集团（天津）股份有限公司 2024 年度股东大会、2025 年第二次 A 股类别股东大会 及 2025 年第二次 H 股类别股东大会的 法律意见 德恒 01G20250006-02 号 致：凯莱英医药集团（天津）股份有限公司 北京德恒律师事务所（以下简称"本所"）接受凯莱英医药集团（天津）股 份有限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会《上市公司股东会规则 ...

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]